Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHRONOS-4: copanlisib plus standard immunochemotherapy versus placebo plus standard immunochemotherapy in relapsed indolent non-Hodgkin lymphoma
MOH_2017-02-09_000101Phase 3Completed
- Sponsor
- Bayer
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in indolent lymphoma comparing Copanlisib + R-CHOP or R-B with Placebo + R-CHOP or R-B (2 arms). Started Nov 2015; status: completed.
02
Drugs
copanlisib
03
Conditions
indolent lymphoma
Beyond the preview
Go deeper on MOH_2017-02-09_000101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-02-09_000101.